Literature DB >> 7986822

The effect of the Z mutation on the ability of alpha 1-antitrypsin to prevent neutrophil mediated tissue damage.

C G Llewellyn-Jones1, D A Lomas, R W Carrell, R A Stockley.   

Abstract

Recent studies have shown that alpha 1-antitrypsin (alpha 1-AT) from Z antitrypsin deficiency subjects has a slightly lower association rate constant with neutrophil elastase (NE) than alpha 1-AT from normal subjects, although it is unknown whether this is of clinical importance. We have purified alpha 1-AT from a normal (M alpha 1-AT) and from a deficient (Z alpha 1-AT) subject and have confirmed that the association rate constants for NE are different (5.28; S.E. 0.06.10(7) M-1 s-1 and 1.2; S.E. 0.2.10(7) M-1 s-1, respectively). We have assessed the ability of both of these proteins to inhibit neutrophil mediated fibronectin (FN) degradation in vitro. Both proteins inhibited FN degradation in a dose dependant manner although Z alpha 1-AT was less effective than M alpha 1-AT at equivalent concentrations of active inhibitor (P < 0.05). Inhibition by M alpha 1-AT was 28.5% S.E. 3.9 at 0.01 microM; 35.5% S.E. 7.3 at 0.1 microM and 37% S.E. 8.4 at 0.5 microM, whereas inhibition by Z alpha 1-AT was 9.25% S.E. 3.9; 19.25% S.E. 7.7 and 21.2% S.E. 9.7, respectively. When the time course of inhibition of FN degradation was studied the difference (although less at 1.0 microM) became greater over the 3 h period of the assay. These results suggest that Z alpha 1-AT is less able than the M phenotype to inhibit connective tissue degradation by neutrophils at equivalent concentrations. This is probably due to the lower association rate constant although the reduced stability of the Z molecule may play a role. The differences, together with the reduced plasma concentration, may accentuate the susceptibility of deficient subjects to the development of emphysema.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7986822     DOI: 10.1016/0925-4439(94)90089-2

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  8 in total

Review 1.  Factors influencing airway inflammation in chronic obstructive pulmonary disease.

Authors:  A Hill; S Gompertz; R Stockley
Journal:  Thorax       Date:  2000-11       Impact factor: 9.139

Review 2.  Genetics and respiratory disease. 2. Alpha 1-antitrypsin deficiency, cirrhosis and emphysema.

Authors:  R Mahadeva; D A Lomas
Journal:  Thorax       Date:  1998-06       Impact factor: 9.139

3.  Quantum proteolysis by neutrophils: implications for pulmonary emphysema in alpha 1-antitrypsin deficiency.

Authors:  E J Campbell; M A Campbell; S S Boukedes; C A Owen
Journal:  J Clin Invest       Date:  1999-08       Impact factor: 14.808

4.  Impact of HIV infection on α1-antitrypsin in the lung.

Authors:  Sarah E Stephenson; Carole L Wilson; Kristina Crothers; Engi F Attia; Cherry Wongtrakool; Irina Petrache; Lynn M Schnapp
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-12-14       Impact factor: 5.464

5.  Chemical chaperones mediate increased secretion of mutant alpha 1-antitrypsin (alpha 1-AT) Z: A potential pharmacological strategy for prevention of liver injury and emphysema in alpha 1-AT deficiency.

Authors:  J A Burrows; L K Willis; D H Perlmutter
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-15       Impact factor: 11.205

Review 6.  Alpha1-antitrypsin deficiency. 4: Molecular pathophysiology.

Authors:  D A Lomas; H Parfrey
Journal:  Thorax       Date:  2004-06       Impact factor: 9.139

7.  Delayed diagnosis of alpha-1-antitrypsin deficiency following post-hepatectomy liver failure: A case report.

Authors:  Benjamin Norton; Jemimah Denson; Christopher Briggs; Matthew Bowles; David Stell; Somaiah Aroori
Journal:  World J Gastroenterol       Date:  2016-03-21       Impact factor: 5.742

8.  The Effects of Maternal Obesity on Porcine Placental Efficiency and Proteome.

Authors:  Ji-Wei Li; Jian Hu; Ming Wei; Ying-Ying Guo; Pei-Shi Yan
Journal:  Animals (Basel)       Date:  2019-08-12       Impact factor: 2.752

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.